Cognition Therapeutics’ (CGTX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report report published on Friday morning,Benzinga reports. They currently have a $4.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Cognition Therapeutics in a report on Thursday, December 4th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $3.33.

Cognition Therapeutics Stock Performance

Shares of CGTX stock opened at $0.73 on Friday. Cognition Therapeutics has a one year low of $0.22 and a one year high of $3.83. The company’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.42. The stock has a market capitalization of $65.23 million, a price-to-earnings ratio of -2.21 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. As a group, research analysts forecast that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Cognition Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. DAVENPORT & Co LLC boosted its position in Cognition Therapeutics by 6.8% during the 4th quarter. DAVENPORT & Co LLC now owns 2,871,836 shares of the company’s stock valued at $3,877,000 after purchasing an additional 182,500 shares during the period. Vanguard Group Inc. grew its stake in Cognition Therapeutics by 105.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after buying an additional 1,377,263 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Cognition Therapeutics by 11,695.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock worth $2,781,000 after buying an additional 2,042,815 shares during the period. Acadian Asset Management LLC increased its position in Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after buying an additional 897,353 shares during the period. Finally, Chescapmanager LLC lifted its stake in Cognition Therapeutics by 98.1% in the third quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock valued at $1,346,000 after buying an additional 493,770 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Q4 / year‑end 2025 results: CGTX reported adjusted results that beat consensus — EPS of ($0.02) vs. ($0.06) expected — signaling a smaller loss than anticipated. MarketBeat Earnings
• Positive Sentiment: Clinical development progress: Management reiterated advancement of zervimesine for DLB psychosis and expects a meeting with the FDA Division of Psychiatry by mid‑2026 — a concrete regulatory milestone that could define next‑step study requirements or timing. GlobeNewswire Release
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target, implying substantial upside versus current levels — a bullish endorsement that could attract longer‑term investors. Benzinga
• Neutral Sentiment: Additional disclosures and call materials: The company published its year‑end 2025 financial report and hosted a management call; full transcripts and summaries are available for investors who want details on pipeline timing, cash position, and management commentary. Earnings Call Transcript
• Negative Sentiment: Heavy selling pressure and volatility: the stock is down sharply on much higher volume than average (several million shares traded vs. an ~943k average), indicating large-scale selling or short‑term profit taking. That flow, combined with typical biotech risks (limited near‑term revenue, potential financing/dilution questions), likely overwhelmed the positive news and pushed the share price lower. MarketBeat Quote

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.